Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection.

Personalized medicine - 1 Jul 2021

Vohra Manik, Sharma Anu Radha, Satyamoorthy Kapaettu, Rai Padmalatha S

Abstract excerpt

Immunomodulatory and analgesic effects of dexamethasone are clinically well established, and this synthetic corticosteroid acts as an agonist of glucocorticoid receptors. Early results of the RECOVERY Trial from the United Kingdom and others suggest certain benefits of dexamethasone against COVID-19 chronic patients. The efforts have been acknowledged by World Health Organization with an interim guideline to use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Drug Treatment
Share to Dexamethasone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to Glucocorticoids

Share to Metabolome

Share to Models, Animal

Share to Pharmaceutical Preparations

Share to Practice Guidelines as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 34086487
DOI: 10.2217/pme-2020-0183
PMCID: PMC8186476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection.PMID 34086487Read ↗

Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic dataSemantic proximity Read ↗

Dexamethasone is a gold weapon for immunomodulation in severe COVID-19 but has no effect on endocrine interleukin 6 and sex-linked response the problem – In silico studySemantic proximity Read ↗

Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screensSemantic proximity Read ↗

RNA-Seq Analysis of Activated PBMC Treated With LMWF5A Predicts an Anti-Inflammatory Mode of Action and Similar Drug Targets to DexamethasoneSemantic proximity Read ↗

Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19Semantic proximity Read ↗

Pharmacogenomics of steroid-induced ocular hypertension: relationship to high-tension glaucomas and new pathophysiologic insightSemantic proximity Read ↗

Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment.Semantic proximity Read ↗

Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatmentSemantic proximity Read ↗

Insights into glucocorticoid responses derived from omics studiesSemantic proximity Read ↗

Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19Semantic proximity Read ↗

Pharmacogenomics of Anti-Inflammatory Therapy: Toward Personalized Use of Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, and BiologicsSemantic proximity Read ↗

The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious DiseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.